
    this study was terminated early due to lack of efficacy based on the results of part i of the
    aurora study.
  
['nonalcoholic steatohepatitis', 'liver cirrhosis', 'non-alcoholic fatty liver disease']
['cenicriviroc']

        Inclusion Criteria:

          -  Successful completion of both Treatment Period 1 and Treatment Period 2, of the
             CENTAUR Study (652-2-203), including a Year 2 liver biopsy.

          -  Completed the AURORA study (3152-301-002) as a result of reaching an adjudicated
             liver-related clinical outcome in Part 1 or Part 2 of the study of:

          -  Histopathological progression to cirrhoses

          -  Model for end-stage liver disease (MELD) score ≥ 15

          -  Ascites (requiring intervention, ie, large volume paracentesis ≥ 1L or initiation of a
             diuretic)

          -  Hospitalization (as defined by a stay of ≥ 24 hours) for onset of variceal bleed,
             hepatic encephalophathy (defined by a West Haven Stage of ≥ 2), spontaneous bacterial
             peritonitis (confirmed by diagnostic paracentesis with positive ascitic fluid
             bacterial culture)

        Exclusion Criteria:

          -  Prior or planned liver transplantation

          -  Other know causes of chronic liver disease such as: Alcoholic liver disease, Primary
             biliary cirrhosis, Primary sclerosing cholangitis, Autoimmune hepatitis, Wilson's
             disease, hemochromatosis, or iron overload, or Alpha-1-antitrypsis (A1AT) deficiency.
      